Tolerance by Engaging Antigen During Cellular Homeostasis (TEACH)
Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)
Sponsor: Immune Tolerance Network (ITN)
A PHASE1 clinical study on Kidney Transplantation and Renal Transplant Recipient, this trial is completed. The trial is conducted by Immune Tolerance Network (ITN) and has accumulated 19 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
19 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 14 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1
-
May 2019 — Apr 2020 [monthly]
Recruiting PHASE1
-
Aug 2018 — May 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Immune Tolerance Network (ITN)
- National Institute of Allergy and Infectious Diseases (NIAID)
- PPD Development, LP
- Rho Federal Systems Division, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .